SEP 2 1 2004 W

Docket No. ORT1590

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : J. Guy BREITENBUCHER, et al.)

Serial No. : 10/075,673) Art Unit 1617

Filed : February 13, 2002)

Title : Method for treating allergies using) substituted pyrazoles)

Examiner : Shengjun WANG)

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EU642141045US in an envelope addressed to: Commissioner For Paytents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Jesús Juanós i Timoneda

(Name of applicant, assignee, or Registered Representative)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on May 19, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

09/24/2004 JADDO1 00000004 100750 10075673

01 FC:1806 180.00 DA

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
☐ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with 🗌 the
first or second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or

in §1.17(p).

an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or \boxtimes Please charge Deposit Account No. 10-0750/ORT1590 /JJiT the fee of \$180.00 as set forth in §1.17(p).In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). \boxtimes Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language, except for those where English language
Abstracts are provided for all those references in foreign languages.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed $\,$.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1590/JJiT. This form is submitted in triplicate.

Respectfully submitted,

Jesús Juands i Timoneda Reg. No. 43,332

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1513

September 21, 2004

DATED:



PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Complete if Known	
Application Number	10/075,673
Filing Date	02/13/02
First Named Inventor	J. Guy BREITENBUCHER
Group Art Unit	1617
Examiner Name	SHENGJUN WANG
Attorney Docket Number	ORT 1590

U.S. PATENT DOCUMENTS

<u> </u>		U.S. Patent D	ocument			
Examiner Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Misc.
	 					
			1 1			

FOREIGN PATENT DOCUMENTS

Examiner Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document			
		Office ³	Number⁴ Ki	ndCode⁵	Applicant of Cited Document	mm-dd-yyyy	Translation	T ⁶
		EP	0254241	A1	Yoshitomi Pharmaceutical Industries, Ltd.	01-27-1988	No	
		EP	0902027	A1	Adir et Compagnie	03-17-1999	Abstract Only	
		GB	1489280		Chugai Pharmaceutical Co., Ltd.	10-19-1977	No	
		JP	50116470		Chugai Pharmaceutical Co., Ltd.	09-11-1975	Abstract Only	
		JP	52014765		Chugai Pharmaceutical Co., Ltd.	02-03-1977	Abstract Only	
		wo	94/18197	A1	Meiji Seika Kabushiki Kaisha	08-18-1994	Abstract Only	
		wo	98/56785	A1	Sumitomo Pharmaceuticals Co., Ltd.	12-17-1998	Abstract Only	
			,					

Examiner	Date	
Signature	Considered	
	 1 000.00.00	<u> </u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov. or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 2 1 2004 Junder the Paperwork Reduction Act of

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE (ct of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Complete if Known	
Application Number	10/075,673
Filing Date	02/13/02
First Named Inventor	J. Guy BREITENBUCHER
Group Art Unit	1617
Examiner Name	SHENGJUN WANG
Attorney Docket Number	ORT 1590

OTHER - NON PATENT LITERATURE DOCUMENTS						
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T²			
	Database CA 'Online! Chemical Abstracts Service, STN database accession no.					
	750.2.7 62 76, 747 662 7 667 56 abstract, (1555), 54(2), 55 161.					
-			-			
			<u> </u>			
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ANDRONATI, S. et al. "Synthesis of 3-Aryl-1-piperzainyl) butyl indazole derivatives and their affinity to 5-HT1 a serotonin and dopamine D1 receptors"	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ANDRONATI, S. et al. "Synthesis of 3-Aryl-1-piperzainyl) butyl indazole derivatives and their affinity to 5-HT1 a serotonin and dopamine D1 receptors" Database CA 'Online! Chemical Abstracts Service, STN database accession no.			

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov. or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS,SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.